255 related articles for article (PubMed ID: 33773378)
1. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
6. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
7. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
[TBL] [Abstract][Full Text] [Related]
9. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
Kitamura N; Hamaguchi M; Nishihara M; Ikumi N; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Oshima M; Asatani S; Kobayashi H; Takei M
Allergol Int; 2021 Jan; 70(1):148-149. PubMed ID: 32967778
[No Abstract] [Full Text] [Related]
10. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature.
André R; Cottin V; Saraux JL; Blaison G; Bienvenu B; Cathebras P; Dhote R; Foucher A; Gil H; Lapoirie J; Launay D; Loustau V; Maurier F; Pertuiset E; Zénone T; Seebach J; Costedoat-Chalumeau N; Puéchal X; Mouthon L; Guillevin L; Terrier B;
Autoimmun Rev; 2017 Sep; 16(9):963-969. PubMed ID: 28709761
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
Pradhan RR; Nepal G; Mandal S
Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
[TBL] [Abstract][Full Text] [Related]
15. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis.
Kolios AGA; Lutterotti A; Kulcsar Z; Renner T; Rudiger A; Nilsson J
Clin Immunol; 2021 Jan; 222():108574. PubMed ID: 32805452
[TBL] [Abstract][Full Text] [Related]
18. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
Ozola L; Aleksejeva E; Stoldere D; Dāvidsone Z; Šantere R; Grantiņa I; Cīrule I; Krams A
Pediatr Pulmonol; 2023 Mar; 58(3):973-979. PubMed ID: 36404638
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]